Robert Yarchoan Robert Yarchoan, MD

Dr. Yarchoan received his M.D. from the University of Pennsylvania. He trained in internal medicine at the University of Minnesota and Immunology in the Metabolism Branch, NCI. He then joined the laboratory of Dr. Samuel Broder, where he played a major role in the development of the first effective therapies for HIV infection, including zidovudine (AZT), didanosine (ddI), and zalcitabine (ddC). In particular, he led the first clinical trials of these drugs, was a co-inventor of didanosine and zalcitabine as AIDS therapies, and led initial studies of combination anti-HIV therapy. He was named chief of the newly formed HIV and AIDS Malignancy Branch in 1996. Since that time, he has focused much of his research on AIDS-related malignancies, especially tumors caused by Kaposi's sarcoma-associated herpesvirus (KSHV).

In December 2007, Dr. Yarchoan was appointed as the first Director of the NCI Office of HIV and AIDS Malignancy (OHAM). This office, which is in the Office of the Director, NCI, coordinates and prioritizes the HIV/AIDS and AIDS malignancy research portfolio throughout the NCI.

This information was provided by the National Institutes of Health.


Jessica Wells Jessica Wells, PhD

Dr. Wells earned her doctoral degree in nursing and completed her postdoctoral fellowship at Nell Hodgson Woodruff School of Nursing, Emory University. She is the first graduate of Emory's BSN to PhD program. Her BSN is from Howard University.

In conjunction with Dr. Rasheeta Chandler, Dr. Wells serves as CFAR's Co-Director of Clinical, Social, and Community Integration. In conjunction with Dr. Theresa Gillespie, Dr. Wells also serves as Co-Director of CFAR's HIV Malignancies Interdisciplinary Research Group

Dr. Well's overarching research focus is cancer control and prevention, specifically to improve cancer outcomes in vulnerable populations with or at risk for cancer. She is particularly interested in cancer prevention and control among those at risk for HIV. Her research has been funded by an NIH National Research Service Award, the American Cancer Society, and Sigma Theta Tau International.

This information was provided by the Winship Cancer Center.


Joseph Lipscomb Joseph Lipscomb, PhD

Dr. Lipscomb is a leading expert in cancer outcomes research and provides insights and direction for issues related to cancer prevention, health disparities, and the growing basic, clinical, and translational research in the area of population sciences.

A Georgia Cancer Coalition Distinguished Cancer Scholar, Dr. Lipscomb is Professor of Health Policy and Management for the Rollins School of Public Health at Emory University. He served as Associate Director for Population Sciences at Winship Cancer Institute from 2010 until 2014.

Dr. Lipscomb is principal investigator on two research grants from the Centers for Disease Control and Prevention, one examining optimal screening for those at elevated risk to breast and colorectal cancer and the other investigating the quality of cancer care for those diagnosed with breast or prostate cancer in Georgia. He is also principal investigator on a grant from the Association of Schools of Public Health and the CDC (funded by NCI and the Georgia Cancer Coalition) to augment the Georgia Comprehensive Cancer Registry with administrative and clinical data from multiple public and private sources to support quality-of-care assessment.

This information was provided by the Winship Cancer Center